Literature DB >> 11432978

C-terminal fragment of amyloid precursor protein induces astrocytosis.

J H Bach1, H S Chae, J C Rah, M W Lee, C H Park, S H Choi, J K Choi, S H Lee, Y S Kim, K Y Kim, W B Lee, Y H Suh, S S Kim.   

Abstract

One of the pathophysiological features of Alzheimer's disease is astrocytosis around senile plaques. Reactive astrocytes may produce proinflammatory mediators, nitric oxide, and subsequent reactive oxygen intermediates such as peroxynitrites. In the present study, we investigated the possible role of the C-terminal fragment of amyloid precursor protein (CT-APP), which is another constituent of amyloid senile plaque and an abnormal product of APP metabolism, as an inducer of astrocytosis. We report that 100 nM recombinant C-terminal 105 amino acid fragment (CT105) of APP induced astrocytosis morphologically and immunologically. CT105 exposure resulted in activation of mitogen-activated protein kinase (MAPK) pathways as well as transcription factor NF-kappaB. Pretreatment with PD098059 and/or SB203580 decreased nitric oxide (NO) production and nuclear factor-kappa B (NF-kappaB) activation. But inhibitors of NF-kappaB activation did not affect MAPKs activation whereas they abolished NO production and attenuated astrocytosis. Furthermore, conditioned media derived from CT105-treated astrocytes enhanced neurotoxicity and pretreatment with NO and peroxynitrite scavengers attenuated its toxicity. These suggest that CT-APP may participate in Alzheimer's pathogenesis through MAPKs- and NF-kappaB-dependent astrocytosis and iNOS induction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11432978     DOI: 10.1046/j.1471-4159.2001.00370.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

Review 1.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

2.  Serum amyloid A1 is involved in amyloid plaque aggregation and memory decline in amyloid beta abundant condition.

Authors:  Soyoung Jang; Woo Young Jang; Minjee Choi; Jinhee Lee; Wookbong Kwon; Junkoo Yi; Si Jun Park; Duhak Yoon; Sanggyu Lee; Myoung Ok Kim; Zae Young Ryoo
Journal:  Transgenic Res       Date:  2019-08-12       Impact factor: 2.788

3.  Early hyperactivity in lateral entorhinal cortex is associated with elevated levels of AβPP metabolites in the Tg2576 mouse model of Alzheimer's disease.

Authors:  Wenjin Xu; Shane Fitzgerald; Ralph A Nixon; Efrat Levy; Donald A Wilson
Journal:  Exp Neurol       Date:  2014-12-12       Impact factor: 5.330

Review 4.  Neuroinflammatory processes in Alzheimer's disease.

Authors:  Michael T Heneka; M Kerry O'Banion; Dick Terwel; Markus Peter Kummer
Journal:  J Neural Transm (Vienna)       Date:  2010-07-15       Impact factor: 3.575

5.  Human brain astrocytes mediate TRAIL-mediated apoptosis after treatment with IFN-gamma.

Authors:  Jeonggi Lee; Jeon-Soo Shin; In-Hong Choi
Journal:  Yonsei Med J       Date:  2006-06-30       Impact factor: 2.759

6.  Effects of nerve growth factor and nitric oxide synthase inhibitors on amyloid precursor protein mRNA levels and protein stability.

Authors:  Janet C Mackinnon; Patricia Huether; Bettina E Kalisch
Journal:  Open Biochem J       Date:  2012-04-19

7.  Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases.

Authors:  Eléonore Beurel
Journal:  Front Mol Neurosci       Date:  2011-08-31       Impact factor: 5.639

8.  Microglia function in Alzheimer's disease.

Authors:  Egle Solito; Magdalena Sastre
Journal:  Front Pharmacol       Date:  2012-02-10       Impact factor: 5.810

9.  Lysosomal dysfunction in the brain of a mouse model with intraneuronal accumulation of carboxyl terminal fragments of the amyloid precursor protein.

Authors:  G Kaur; M Pawlik; S E Gandy; M E Ehrlich; J F Smiley; E Levy
Journal:  Mol Psychiatry       Date:  2016-10-25       Impact factor: 15.992

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.